تداخلات فلوتيكازون وسالميتيرول

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (نشرة أبيراتيرون، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة أداليموماب، تحذير مؤطر)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (نشرة أكسيتينيب، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (نشرة إمتريسيتابين وريلبيفيرين وتينوفوفير، موانع الاستعمال)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة إنفليكسيماب، تحذير مؤطر)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة أوباداسيتينيب، تحذير مؤطر)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة إيتانرسبت، تحذير مؤطر)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (نشرة إيميبرامين، التداخلات الدوائية)

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة باريسيتينيب، تحذير مؤطر)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (نشرة تراندولابريل، التحذيرات)

…(SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine. (نشرة ترانيلسيبرومين، تحذير مؤطر)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (نشرة تريتينوين، تحذير مؤطر)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة توسيليزوماب، تحذير مؤطر)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (نشرة توفاسيتينيب، تحذير مؤطر)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (نشرة ثالث أكسيد الزرنيخ، تحذير مؤطر)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (نشرة درونابينول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (نشرة دوسيتاكسيل، التحذيرات والاحتياطات)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (نشرة روفلوميلاست، التحذيرات والاحتياطات)

IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS ). (نشرة ريبافيرين، تحذير مؤطر)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (نشرة ريلبيفيرين، موانع الاستعمال)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (نشرة سوماتروبين، التداخلات الدوائية)

In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (نشرة سيروليموس، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

The potentiation of sympathomimetic substances and related compounds by MAO inhibitors may result in hypertensive crises (see WARNINGS ). (نشرة فينيلزين، موانع الاستعمال)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Known Hypersensitivity or Idiosyncrasy to the Sympathomimetic Amines NUMBRINO is contraindicated in patients with a known history of hypersensitivity to cocaine or to the components of the nasal solution. (نشرة كوكايين، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (نشرة لوفاستاتين، موانع الاستعمال)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (نشرة ليفوثيروكسين وليوثيرونين، تحذير مؤطر)

Avoid Excessive Use of Fluticasone Propionate/Salmeterol and Avoid Use with Other Long-Acting Beta 2 -Agonists Fluticasone Propionate/Salmeterol MDPI should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (نشرة ليوثيرونين، تحذير مؤطر)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (نشرة موكسيبريل، التحذيرات)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (نشرة ميتوتان، تحذير مؤطر)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Albuterol (or other beta 2 agonists): Increase the frequency of monitoring blood pressure and heart rate. (نشرة أتوموكسيتين، التداخلات الدوائية)

Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (نشرة أتينولول، التحذيرات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (نشرة إرلوتينيب، التحذيرات والاحتياطات)

Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (نشرة أزتريونام، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

The chance is higher if you are age 60 or older take a blood thinning (anticoagulant) or steroid drug have 3 or more alcoholic drinks every day while using this product have had stomach ulcers or bleeding problems take more or for a longer time than directed take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others]… (نشرة أسبرين، التحذيرات)

Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively. (نشرة إستراديول، الاحتياطات)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins [see Warnings and Precautions ( 5.11 ) and Drug Interactions ( 7.2 )]. (نشرة إستراديول ودينوجيست، التداخلات الدوائية)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (نشرة إستراديول ونوريثيستيرون، التحذيرات والاحتياطات)

Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), SHBG, leading to increased total circulating corticosteroids and sex steroids respectively. (نشرة إستروجينات مقترنة، الاحتياطات)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (نشرة إستروجينات مقترنة وبازيدوكسيفين، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Sympathomimetic drugs: Dose adjustment needed (7) (نشرة إسمولول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (نشرة أفاتينيب، التحذيرات والاحتياطات)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (نشرة أكليدينيوم، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة البلادونا والأفيون، التحذيرات والاحتياطات)

If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (نشرة ألبيليسيب، التحذيرات والاحتياطات)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (نشرة ألبيندازول، التحذيرات والاحتياطات)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (نشرة ألوغليبتين وميتفورمين، التداخلات الدوائية)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (نشرة أليسكيرين، التحذيرات والاحتياطات)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (نشرة إليكساكافتور وتيزاكافتور وإيفاكافتور، التحذيرات والاحتياطات)

Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (نشرة أليمتوزوماب، التحذيرات والاحتياطات)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (نشرة أليندرونات، التحذيرات والاحتياطات)

Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (نشرة أمفوتيريسين ب، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة إندوميثاسين، التحذيرات والاحتياطات)

…Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (نشرة إنسولين أسبارت، التداخلات الدوائية)

…Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (نشرة إنسولين ديتيمير، التداخلات الدوائية)

…Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (نشرة إنسولين ديغلوديك، التداخلات الدوائية)

…Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (نشرة إنسولين غلارجين، التداخلات الدوائية)

…Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (نشرة إنسولين ليسبرو، التداخلات الدوائية)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (نشرة أوفلوكساسين، التحذيرات)

In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (نشرة أوكريليزوماب، التحذيرات والاحتياطات)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة أوكسابروزين، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة أوكسيكودون، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة أوكسيكودون وباراسيتامول، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة أوكسيمورفون، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة أوليسيريدين، التحذيرات والاحتياطات)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (نشرة أوماليزوماب، التحذيرات والاحتياطات)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (نشرة إيباندرونات، التحذيرات والاحتياطات)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة إيبوبروفين، التحذيرات والاحتياطات)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة إيبوبروفين وفاموتيدين، التحذيرات والاحتياطات)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (نشرة إيترافيرين، التداخلات الدوائية)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (نشرة إيتودولاك، التحذيرات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

The amount of both steroids should be considered in the choice of an oral contraceptive. (نشرة إيثينوديول ثنائي الأسيتات وإيثينيل إستراديول، التحذيرات)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (نشرة إيفرمكتين، التحذيرات)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة باراسيتامول وإيبوبروفين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة باراسيتامول وكودايين، التحذيرات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (نشرة باسيريوتيد، التحذيرات والاحتياطات)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (نشرة باميدرونات، التحذيرات والاحتياطات)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (نشرة بروبوفول، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بروميثازين وكودايين، التحذيرات والاحتياطات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Hypercorticism and Adrenal Suppression Fluticasone propionate, a component of Fluticasone Propionate/Salmeterol MDPI, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بنتازوسين ونالوكسون، التحذيرات)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (نشرة بنراليزوماب، التحذيرات والاحتياطات)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (نشرة بنسيلامين، التحذيرات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوبرينورفين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوبرينورفين ونالوكسون، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتورفانول، التحذيرات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (نشرة بورتيزوميب، التحذيرات والاحتياطات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (نشرة بونيسيمود، التحذيرات والاحتياطات)

Since β 1 -selectivity is not absolute and is inversely related to dose, the lowest possible dose of betaxolol should be used (5 to 10 mg once daily) and a bronchodilator should be made available. (نشرة بيتاكسولول، التحذيرات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بيثيدين، التحذيرات والاحتياطات)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة بيروكسيكام، التحذيرات والاحتياطات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (نشرة بيكتيغرافير وإمتريسيتابين وتينوفوفير ألافيناميد، التداخلات الدوائية)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (نشرة بينداموستين، التحذيرات والاحتياطات)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (نشرة بيوغليتازون وغليميبيريد، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة تابنتادول، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (نشرة تراستوزوماب، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة ترامادول، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة ترامادول وباراسيتامول، التحذيرات والاحتياطات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (نشرة تستوستيرون، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (نشرة تولكابون، التداخلات الدوائية)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (نشرة تولميتين، التحذيرات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (نشرة تيريباراتيد، التحذيرات والاحتياطات)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (نشرة تيساموريلين، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (نشرة تيمسيروليموس، التحذيرات والاحتياطات)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (نشرة تيموزولوميد، التحذيرات والاحتياطات)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (نشرة تيوتروبيوم، التداخلات الدوائية)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (نشرة ثيوفيلين، التحذيرات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (نشرة حمض الزوليدرونيك، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (نشرة حمض الميفيناميك، التحذيرات والاحتياطات)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (نشرة دابتومايسين، التحذيرات والاحتياطات)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (نشرة دوبيلوماب، التحذيرات والاحتياطات)

Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (نشرة دوكسابرام، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (نشرة ديجوكسين، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Sex hormone binding globulins are increased and result in elevated levels of total circulating sex steroids however, free or biologically active levels either decrease or remain unchanged. e. (نشرة ديسوجيستريل وإيثينيل إستراديول، الاحتياطات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (نشرة ديسيكلومين، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (نشرة ديفلونيزال، التحذيرات)

…darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan,… (نشرة ديفيراسيروكس، التداخلات الدوائية)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة ديكلوفيناك، التحذيرات والاحتياطات)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة ديكلوفيناك وميزوبروستول، التحذيرات والاحتياطات)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (نشرة دينوسوماب، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (نشرة روكورونيوم، التحذيرات والاحتياطات)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (نشرة ريزيدرونات، التحذيرات والاحتياطات)

…Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants… (نشرة ريفابنتين، التداخلات الدوائية)

…Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as a single oral dose 8 hours before administering a single oral dose of nifedipine 10 mg Decrease exposure Verapamil Decrease exposure Corticosteroids Numerous cases in the literature describe a decrease in glucocorticoid effect when used concomitantly with rifampin. (نشرة ريفامبيسين، التداخلات الدوائية)

If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (نشرة زاناميفير، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (نشرة زينوكوتوزوماب، التحذيرات والاحتياطات)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (نشرة سالسالات، التحذيرات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (نشرة سكسينيل كولين، التداخلات الدوائية)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (نشرة سوتالول، التداخلات الدوائية)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (نشرة سولينداك، التحذيرات)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة سوماتريبتان ونابروكسين، التحذيرات والاحتياطات)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (نشرة سيبروفلوكساسين، التحذيرات والاحتياطات)

These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (نشرة سيتارابين، التحذيرات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (نشرة سيفوكسيتين، التحذيرات والاحتياطات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة سيليكوكسيب، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

…olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (نشرة غليبيزيد، التداخلات الدوائية)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (نشرة غليسرول فينيل بوتيرات، التداخلات الدوائية)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (نشرة غليميبيريد، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (نشرة فلوربيبروفين، التحذيرات والاحتياطات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة فنتانيل، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (نشرة فينغوليمود، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة فينوبروفين، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (نشرة فينيل أسيتات الصوديوم وبنزوات الصوديوم، التداخلات الدوائية)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (نشرة فينيل بوتيرات الصوديوم، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (نشرة كلادريبين، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة كودايين، التحذيرات والاحتياطات)

Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (نشرة كيتامين، التحذيرات والاحتياطات)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (نشرة كيتوبروفين، التحذيرات والاحتياطات)

In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (نشرة كيتورولاك، التحذيرات والاحتياطات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. (نشرة ليفوثيروكسين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة ليفورفانول، التحذيرات)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (نشرة ليفوفلوكساسين، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Thyroid Hormone Replacement Therapy or Corticosteroid Replacement Therapy Clinical effect Concomitant use of CHCs with thyroid hormone replacement therapy or corticosteroid replacement therapy may increase systemic exposure of thyroid-binding and cortisol-binding globulin [see Warnings and Precautions (5.11) ]. (نشرة ليفونورجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (نشرة مارجيتوكسيماب، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة مورفين، التحذيرات والاحتياطات)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (نشرة موكسيفلوكساسين، التحذيرات والاحتياطات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Inhaled corticosteroid may be reduced gradually. (نشرة مونتيلوكاست، التحذيرات والاحتياطات)

Decrease corticosteroids gradually, if appropriate. (نشرة ميبوليزوماب، التحذيرات والاحتياطات)

Bronchodilators, including beta 2 -agonists, should be readily available or administered concomitantly [see Dosage and Administration (2) ]. (نشرة ميتوبرولول، التحذيرات والاحتياطات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

This can be corrected by giving appropriate doses of corticosteroids. (نشرة ميتيرابون، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة ميثادون، التحذيرات والاحتياطات)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (نشرة ميثازولاميد، التداخلات الدوائية)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (نشرة ميثوتريكسات، التداخلات الدوائية)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (نشرة ميثيل تستوستيرون، التحذيرات)

If not, corticosteroids may be given and other causes of anemia should be considered. (نشرة ميثيل دوبا، التحذيرات)

Laboratory evaluation for adrenal insufficiency and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. (نشرة ميجيسترول، التحذيرات والاحتياطات)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (نشرة ميدروكسي بروجستيرون، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة ميلوكسيكام، التحذيرات والاحتياطات)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة نابروكسين، التحذيرات والاحتياطات)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (نشرة نابروكسين وإيزوميبرازول، التحذيرات والاحتياطات)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (نشرة نابوميتون، التحذيرات)

In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (نشرة ناتاليزوماب، التحذيرات والاحتياطات)

Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (نشرة ناتيغلينيد، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة نالبوفين، التحذيرات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (نشرة نينتيدانيب، التحذيرات والاحتياطات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (نشرة هالوبيريدول، التداخلات الدوائية)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (نشرة هيدرالازين، التحذيرات)

Diuretics: Use with caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة هيدروكودون، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة هيدروكودون وإيبوبروفين، التحذيرات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة هيدروكودون وباراسيتامول، التحذيرات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة هيدروكودون وكلورفينيرامين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة هيدروكودون وهوماتروبين، التحذيرات والاحتياطات)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة هيدرومورفون، التحذيرات والاحتياطات)

More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [ see Boxed Warning ]. (نشرة وارفارين، التداخلات الدوائية)

If paradoxical bronchospasm occurs following dosing with inhaled fluticasone propionate/salmeterol medicines, it should be treated immediately with an inhaled, short-acting bronchodilator; inhaled fluticasone propionate/salmeterol medicines should be discontinued immediately; and alternative therapy should be instituted. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (نشرة أسيبوتولول، التحذيرات)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (نشرة أكاربوز، التداخلات الدوائية)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (نشرة ألتيبلاز، التحذيرات والاحتياطات)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (نشرة إمباغليفلوزين وميتفورمين، التداخلات الدوائية)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (نشرة أمبيسيلين، التحذيرات)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (نشرة أميكاسين، التحذيرات والاحتياطات)

If paradoxical bronchospasm occurs following dosing with inhaled fluticasone propionate/salmeterol medicines, it should be treated immediately with an inhaled, short-acting bronchodilator; inhaled fluticasone propionate/salmeterol medicines should be discontinued immediately; and alternative therapy should be instituted. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. (نشرة إنسولين عادي (بشري)، التحذيرات والاحتياطات)

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (نشرة أوستيكينوماب، التحذيرات والاحتياطات)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (نشرة أوكساسيلين، التحذيرات)

If paradoxical bronchospasm occurs following dosing with inhaled fluticasone propionate/salmeterol medicines, it should be treated immediately with an inhaled, short-acting bronchodilator; inhaled fluticasone propionate/salmeterol medicines should be discontinued immediately; and alternative therapy should be instituted. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (نشرة إيتونوجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while treatment with Fluticasone Propionate/Salmeterol MDPI continues, but at times therapy with Fluticasone Propionate/Salmeterol MDPI may need to be interrupted. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (نشرة بروبيل ثيوراسيل، التحذيرات)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (نشرة بروموكريبتين، التداخلات الدوائية)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (نشرة بنسلين G، التحذيرات)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (نشرة بنسلين V، التحذيرات)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (نشرة بوسلفان، التحذيرات)

A beta 2 agonist (bronchodilator) should be made available. (نشرة بيسوبرولول، التحذيرات)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (نشرة بيفاسيزوماب، التحذيرات والاحتياطات)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (نشرة بيوغليتازون وميتفورمين، التداخلات الدوائية)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (نشرة توبرامايسين، التداخلات الدوائية)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (نشرة تينيكتيبلاز، التحذيرات والاحتياطات)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (نشرة حمض البيمبيدويك، التحذيرات والاحتياطات)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (نشرة داباغليفلوزين وميتفورمين، التداخلات الدوائية)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (نشرة داساتينيب، التحذيرات والاحتياطات)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (نشرة دروبيريدول، التداخلات الدوائية)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (نشرة دروسبيرينون وإيثينيل إستراديول، التحذيرات والاحتياطات)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (نشرة رالوكسيفين، التداخلات الدوائية)

…antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (نشرة ريباغلينيد، التداخلات الدوائية)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (نشرة ريتوكسيماب، التحذيرات والاحتياطات)

Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (نشرة زيبراسيدون، التحذيرات والاحتياطات)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (نشرة ساكساغليبتين وميتفورمين، التداخلات الدوائية)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (نشرة سيتاغليبتين وميتفورمين، التداخلات الدوائية)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفادروكسيل، التحذيرات والاحتياطات)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفاكلور، التحذيرات)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفبروزيل، التحذيرات)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفتازيديم، التحذيرات)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (نشرة سيفترياكسون، التحذيرات والاحتياطات)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفدينير، التحذيرات)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (نشرة سيفوتيتان، التحذيرات)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (نشرة غلوكاغون، التحذيرات والاحتياطات)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (نشرة غليبنكلاميد، التداخلات الدوائية)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (نشرة غليبنكلاميد وميتفورمين، التداخلات الدوائية)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (نشرة غليبيزيد وميتفورمين، الاحتياطات)

TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (نشرة غوسيلكوماب، التحذيرات والاحتياطات)

Steroids may or may not be effective in controlling these hemolytic episodes. (نشرة فلودارابين، التحذيرات والاحتياطات)

الكورتيكوستيرويدات مثل بريدنيزون تقلّل امتصاص الكالسيوم وتخلّ باستقلاب فيتامين د، مما يسهم في فقدان العظم. (NIH Office of Dietary Supplements, Vitamin D)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (نشرة كالسيتريول، التداخلات الدوائية)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while treatment with Fluticasone Propionate/Salmeterol MDPI continues, but at times therapy with Fluticasone Propionate/Salmeterol MDPI may need to be interrupted. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (نشرة كلوفارابين، التحذيرات والاحتياطات)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (نشرة كلوميفين، التحذيرات)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (نشرة كورتيكوتروبين، التحذيرات والاحتياطات)

Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (نشرة كينين، التداخلات الدوائية)

Beta blockers antagonize the bronchodilator effect of beta-receptor agonists. (نشرة لابيتالول، التداخلات الدوائية)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (نشرة ليناغليبتين وميتفورمين، التداخلات الدوائية)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (نشرة ليناليدوميد، التحذيرات والاحتياطات)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (نشرة ميتفورمين، التداخلات الدوائية)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (نشرة ميتوكسانترون، التداخلات الدوائية)

Intra-arterial glucocorticoid injection at the site of injury, followed by systemic steroids. (نشرة ميثوهيكسيتال، التحذيرات)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (نشرة ميثيمازول، التحذيرات)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while treatment with Fluticasone Propionate/Salmeterol MDPI continues, but at times therapy with Fluticasone Propionate/Salmeterol MDPI may need to be interrupted. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (نشرة ميلفالان، التحذيرات)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (نشرة نالتريكسون، التحذيرات والاحتياطات)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (نشرة نورجيستريل وإيثينيل إستراديول، الاحتياطات)

Interactions with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (نشرة نورجيستيمات وإيثينيل إستراديول، التداخلات الدوائية)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (نشرة نوريثيستيرون وإيثينيل إستراديول، التحذيرات والاحتياطات)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (نشرة نوريلجيسترومين وإيثينيل إستراديول، التداخلات الدوائية)